查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1798030

2032 年自體免疫皮膚病治療市場預測：按疾病類型、治療類型、給藥途徑、最終用戶和地區進行的全球分析

Autoimmune Skin Diseases Treatment Market Forecasts to 2032 - Global Analysis By Disease Type, Therapy Type, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球自體免疫皮膚病治療市場預計在 2025 年達到 100.5 億美元，到 2032 年將達到 257.7 億美元，預測期內的複合年成長率為 14.4%。

「皮膚自體免疫疾病治療」指用於治療因免疫系統無意中攻擊健康皮膚細胞而引起的皮膚疾病的醫療程序。乾癬、白斑、紅斑性狼瘡、硬皮症、天皰瘡和皰疹性皮膚炎都是這類疾病。治療的主要目標是盡量減少皮膚損傷、減輕發炎、抑制異常免疫反應、緩解症狀並避免病情復發。常見的治療方法方法包括全身性和局部使用皮質類固醇、免疫抑制劑、生技藥品、照光治療和支持性護膚。改善生活品質、減少併發症和減緩病情進展都依賴早期診斷和針對每位患者的個人化治療策略。

自體免疫皮膚病盛行率不斷上升

篩檢的提高和認知度的提升，使得白斑症、狼瘡和牛皮癬等疾病的診斷率不斷上升。不斷擴大的患者群體促使醫療保健專業人員採用標靶治療、免疫調節劑和先進的生技藥品。為了滿足這些患者尚未滿足的需求，藥廠正在​​加大研發投入。此外，有利的醫療法規和皮膚病治療可近性的改善，也推動了治療的採用率不斷提高。自體免疫皮膚病的盛行率不斷上升，推動了市場的穩定擴張。

生技藥品和先進療法成本高昂

許多患者無力承擔這些藥物，限制了藥物的可近性和依從性。高昂的費用也給保險公司和醫療保健系統帶來壓力，導致覆蓋範圍有限，報銷困難。患者可能會選擇療效較差的治療方案。這些經濟障礙阻礙了最先進治療的廣泛應用，並限制了市場成長。

醫療支出和診斷成長

增加津貼，鼓勵使用尖端生技藥品和針對性治療方法，將改善患者的治療效果。診斷能力的進步將使疾病分類更加準確，並實現更早的發現。透過早期準確的診斷進行及時干預，將減緩疾病進展和併發症。隨著醫療基礎設施的發展，都市區將有可能提高治療的可近性。這些因素將共同增加對自體免疫皮膚病治療的需求，從而推動市場成長。

安全性問題和副作用

許多治療方法都存在嚴重副作用的風險，例如感染疾病和器官損傷。這些健康危害可能導致患者避免或停止治療。此外，如果某些藥物的安全性較差，醫生可能不願意推薦。這導致患者依從性和市場接受度較低。因此，對風險的擔憂阻礙了有益藥物的採用。

COVID-19的影響

新冠疫情對自體免疫皮膚病治療市場造成了重大衝擊，擾亂了供應鏈，推遲了臨床試驗，並限制了患者就醫。醫療資源的關閉和重新分配推遲了診斷和治療時間，影響了患者的治療效果。遠端醫療的普及加速，使得遠距會診和藥物配製管理成為可能。製藥公司在生產和分銷方面面臨挑戰，但同時，他們也更專注於開發先進的治療方法。疫情後的復甦將由選擇性治療的恢復、醫療保健可近性的改善以及對自體免疫皮膚病管理意識的提高所推動。

生技藥品領域預計將成為預測期內最大的細分市場

生技藥品領域預計將在預測期內佔據最大的市場佔有率，這得益於其提供針對潛在免疫功能障礙的標靶治療。與傳統藥物相比，這些療法療效較佳、緩解期更長，刺激了患者需求。生技藥品及其給藥方式的進步提高了安全性和便利性，從而提高了採用率。用於治療牛皮癬和異位性皮膚炎等疾病的新型生技藥品的核准不斷增加，擴大了治療組合。醫療保健提供者和患者意識的不斷增強，進一步推動了生技藥品市場的成長。

預計預測期內居家照護領域將以最高的複合年成長率成長。

預計居家照護領域將在預測期內實現最高成長率，因為患者可以在家中便捷地接受治療和監測，從而減少頻繁就醫的需求。自我給藥選項和醫療保健提供者的遠距指導也有助於提高治療依從性。行動裝置和遠端醫療的進步使居家照護更加可行。整體而言，居家照護可以改善患者的治療效果，同時降低醫療成本，進而推動市場成長。

比最大的地區

預計北美地區將在預測期內佔據最大的市場佔有率，這得益於其高發病率、完善的醫療基礎設施和雄厚的研發資金。先進藥物，尤其是生技藥品和JAK抑制劑，以及優惠的報銷政策，正在支持新治療方法的快速應用。監管機構正在加速藥品核准，並鼓勵生物相似藥的上市。尖端診斷和精準醫療技術（例如基於人工智慧的成像和多重檢測）的使用日益增多，以及生物技術公司和學術機構之間的戰略合作夥伴關係，正在推動牛皮癬、濕疹和狼瘡等疾病治療方法的持續創新。

複合年成長率最高的地區

預計亞太地區在預測期內的複合年成長率最高，這主要得益於人口老化、都市化和生活方式的改變導致自體免疫疾病盛行率上升。醫療基礎設施投資、公共保險覆蓋範圍的擴大以及學名藥的生產將提高治療的可及性。新興技術包括人工智慧遠端皮膚病學、移動診斷、高光譜影像以及正在開發的奈米結構局部治療。全球創新趨勢強調經濟高效的在地化解決方案，並透過與全球製藥公司的合作，支援根據本地需求和醫療保健差異客製化診斷和精準醫療的可擴展部署。

免費客製化服務

訂閱此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場參與企業進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 透過產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球自體免疫皮膚病治療市場（依疾病類型）

  • 介紹
  • 銀屑病
  • 異位性皮膚炎
  • 白斑
  • 尋常型天皰瘡
  • 紅斑狼瘡
  • 其他

6. 全球自體免疫皮膚病治療市場（依治療類型）

  • 介紹
  • 生技藥品
  • 皮質類固醇
  • 免疫抑制劑
  • 小分子藥物
  • 其他

7. 全球自體免疫皮膚病治療市場（依給藥途徑）

  • 介紹
  • 口服
  • 注射
  • 局部的

8. 全球自體免疫皮膚病治療市場（依最終用戶）

  • 介紹
  • 醫院
  • 專科診所
  • 居家照護
  • 其他

9. 全球自體免疫皮膚病治療市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要發展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Biogen Inc.
  • Sanofi SA
  • UCB SA
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Roche Holding AG
  • Horizon Therapeutics plc
  • Incyte Corporation
Product Code: SMRC30400

According to Stratistics MRC, the Global Autoimmune Skin Diseases Treatment Market is accounted for $10.05 billion in 2025 and is expected to reach $25.77 billion by 2032 growing at a CAGR of 14.4% during the forecast period. Autoimmune Conditions of the Skin the term "treatment" describes the medical procedures used to treat skin conditions brought on by the immune system inadvertently targeting healthy skin cells. Psoriasis, vitiligo, lupus erythematosus, scleroderma, pemphigus, and dermatitis herpetiformis are some of these ailments. The main goals of treatment are to minimise skin damage, reduce inflammation, inhibit aberrant immune responses, relieve symptoms, and avoid flare-ups. Systemic and topical corticosteroids, immune-suppressants, biologic treatments, phototherapy, and supportive skincare are common methods. Improving quality of life, decreasing complications, and delaying the progression of disease all depend on early diagnosis and individualized treatment strategies.

Market Dynamics:

Driver:

Rising prevalence of autoimmune skin conditions

Improved screening and more awareness have led to a rise in the diagnosis of conditions like vitiligo, lupus, and psoriasis. Healthcare professionals are adopting targeted treatments, immune-modulators, and sophisticated biologics as a result of this expanding patient base. To meet these patients' unmet requirements, pharmaceutical companies are increasing their research and development expenditures. Treatment adoption rates are also increased by favourable healthcare regulations and improved access to dermatological care. All things considered, the growing prevalence of autoimmune skin conditions drives steady market expansion.

Restraint:

High cost of biologic and advanced therapies

The inability of many patients to pay for these medicines restricts their access and adherence. High costs also put a strain on insurance companies and healthcare systems. This results in limited coverage and difficulties with reimbursement. Patients might choose less effective options as a result. These monetary obstacles hinder the uptake of cutting-edge treatments and limit market growth.

Opportunity:

Growth in healthcare expenditure and diagnostics

Patient outcomes are improved by increased funding, which encourages the use of cutting-edge biologics and focused treatments. More precise disease classification and earlier detection are made possible by advancements in diagnostic capabilities. Timely intervention by early and accurate diagnosis slows the progression and complications of disease. Increased access to treatment in both urban and rural areas is made possible by growing healthcare infrastructure. These elements work together to increase demand and grow the market for treatments for autoimmune skin conditions.

Threat:

Safety concerns and adverse effects

The danger of serious side effects, like infections or organ damage, is present with many treatments. These health hazards may cause patients to avoid or stop receiving therapy. Additionally, doctors can be reluctant to recommend particular medications if their safety profiles are weak. Patient compliance and market acceptance are lowered as a result. Therefore, the adoption of beneficial medicines is slowed by the fear of danger.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Autoimmune Skin Diseases Treatment Market by disrupting supply chains, delaying clinical trials, and limiting patient access to healthcare facilities. Lockdowns and healthcare resource reallocation led to postponed diagnoses and treatment schedules, impacting patient outcomes. Telemedicine adoption accelerated, enabling remote consultations and prescription management. Pharmaceutical companies faced challenges in production and distribution but also saw increased focus on developing advanced therapies. Post-pandemic recovery is driven by resumed elective treatments, improved healthcare accessibility, and growing awareness of autoimmune skin disease management.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period by offering targeted therapies that address the underlying immune system dysfunction. These treatments provide higher efficacy and longer remission periods compared to conventional drugs, boosting patient demand. Advancements in biologic formulations and delivery methods enhance safety and convenience, increasing adoption rates. Growing approvals of novel biologics for conditions like psoriasis and atopic dermatitis expand the treatment portfolio. Rising awareness among healthcare providers and patients further accelerates market growth for biologics.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by offering patients convenient access to therapies and monitoring in their own homes, reducing the need for frequent hospital visits. It supports better treatment adherence through self-administration options and remote guidance from healthcare providers. Advancements in portable devices and telemedicine enhance the feasibility of home-based care. Overall, homecare settings improve patient outcomes while lowering healthcare costs, driving market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share is driven by high disease prevalence, well developed healthcare infrastructure, and robust research funding. Advanced pharmaceuticals particularly biologics and JAK inhibitors plus favourable reimbursement policies support rapid adoption of novel therapies. Regulatory agencies facilitate accelerated drug approvals and bio similar entry. Cutting edge diagnostic and precision medicine technologies, including AI assisted imaging and multiplex assays, are increasingly used, with strategic collaborations between biotech firms and academic institutions powering continuous innovation in therapies for conditions such as psoriasis, eczema and lupus.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR is fuelled by rising autoimmune disease incidence tied to aging populations, urbanization and evolving lifestyles. Investments in healthcare infrastructure, expansion of public insurance coverage and generics production bolster treatment access. Emerging technologies include AI enabled teledermatology, mobile diagnostics, and hyper spectral imaging and nanostructure topical therapeutics under development. Regional innovation trends emphasize cost-effective, localized solutions-often in collaboration with global pharma supporting scalable deployment of diagnostics and precision therapies tailored to regional needs and healthcare disparities.

Key players in the market

Some of the key players in Autoimmune Skin Diseases Treatment Market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, Biogen Inc., Sanofi S.A., UCB S.A., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Horizon Therapeutics plc and Incyte Corporation.

Key Developments:

In April 2025, Amgen announced a $900 million expansion of its New Albany, Ohio biomanufacturing facility. The investment aims to boost production capacity for both pipeline and commercial biologics, potentially supporting treatments in autoimmune dermatology. This expansion strengthens Amgen's manufacturing network to meet growing global demand for innovative therapies.

In January 2025, AbbVie completed its ~$200 million acquisition of Nimble Therapeutics, gaining its lead oral peptide IL 23 receptor inhibitor for psoriasis and inflammatory bowel disease, along with Nimble's proprietary peptide drug discovery platform to advance targeted autoimmune disease therapies.

In June 2023, Eli Lilly agreed to acquire Dice Therapeutics for $2.4 billion in cash (approximately $48 per share). The deal focuses on Dice's innovative oral IL 17 inhibitors, notably DC 806 in phase II psoriasis trials, along with other pipeline assets aimed at advancing treatments for autoimmune and inflammatory skin diseases.

Disease Types Covered:

  • Psoriasis
  • Atopic Dermatitis
  • Vitiligo
  • Pemphigus Vulgaris
  • Lupus Erythematosus
  • Other Disease Types

Therapy Types Covered:

  • Biologics
  • Corticosteroids
  • Immunosuppressants
  • Small Molecule Drugs
  • Other Therapy Types

Route of Administrations Covered:

  • Oral
  • Injectable
  • Topical

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoimmune Skin Diseases Treatment Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Psoriasis
  • 5.3 Atopic Dermatitis
  • 5.4 Vitiligo
  • 5.5 Pemphigus Vulgaris
  • 5.6 Lupus Erythematosus
  • 5.7 Other Disease Types

6 Global Autoimmune Skin Diseases Treatment Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Biologics
  • 6.3 Corticosteroids
  • 6.4 Immunosuppressants
  • 6.5 Small Molecule Drugs
  • 6.6 Other Therapy Types

7 Global Autoimmune Skin Diseases Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Topical

8 Global Autoimmune Skin Diseases Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare Settings
  • 8.5 Other End Users

9 Global Autoimmune Skin Diseases Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AbbVie Inc.
  • 11.2 Amgen Inc.
  • 11.3 Eli Lilly and Company
  • 11.4 Johnson & Johnson Services, Inc.
  • 11.5 Novartis AG
  • 11.6 Pfizer Inc.
  • 11.7 Bristol Myers Squibb Company
  • 11.8 Biogen Inc.
  • 11.9 Sanofi S.A.
  • 11.10 UCB S.A.
  • 11.11 GlaxoSmithKline plc
  • 11.12 Regeneron Pharmaceuticals, Inc.
  • 11.13 AstraZeneca plc
  • 11.14 Merck & Co., Inc.
  • 11.15 Takeda Pharmaceutical Company Limited
  • 11.16 Roche Holding AG
  • 11.17 Horizon Therapeutics plc
  • 11.18 Incyte Corporation

List of Tables

  • Table 1 Global Autoimmune Skin Diseases Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 3 Global Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 4 Global Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 5 Global Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 6 Global Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 7 Global Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 8 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 9 Global Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 10 Global Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 11 Global Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 12 Global Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 13 Global Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 14 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 15 Global Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 16 Global Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 17 Global Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 18 Global Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 19 Global Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 22 Global Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 23 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 24 North America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 25 North America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 26 North America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 27 North America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 28 North America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 29 North America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 30 North America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 31 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 32 North America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 33 North America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 34 North America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 35 North America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 36 North America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 37 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 38 North America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 39 North America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 40 North America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 41 North America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 42 North America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 43 North America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 44 North America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 45 North America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 46 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 47 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 48 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 49 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 50 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 51 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 52 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 53 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 54 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 55 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 56 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 57 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 58 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 59 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 60 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 61 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 62 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 63 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 64 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 65 Europe Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 66 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 67 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 68 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 69 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 70 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 71 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 72 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 73 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 74 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 75 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 76 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 77 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 78 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 79 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 80 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 81 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 82 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 83 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 84 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 85 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 86 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 87 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 88 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 89 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 90 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 91 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 92 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 93 South America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 94 South America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 95 South America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 96 South America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 97 South America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 98 South America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 99 South America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 100 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 101 South America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 102 South America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 103 South America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 104 South America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 105 South America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 106 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 107 South America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 108 South America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 109 South America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 110 South America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 111 South America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 112 South America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 113 South America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 114 South America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 115 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 116 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 117 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 118 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 119 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 120 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 121 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 122 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 123 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 124 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 125 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 126 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 127 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 128 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 129 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 130 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 131 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 132 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 133 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 134 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 135 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 136 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 137 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 138 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)